Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CCR2 | P41597 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777123 | 0.93 | POLB (0.56) | ALDH1A1POLBMEN1KMT2ACCR2 | |
| SCHEMBL3783226 | 0.89 | CCR2 (0.49) | ALDH1A1POLBCCR2KCNH2 | |
| SCHEMBL3770723 | 0.87 | POLB (0.57) | ALDH1A1POLBMEN1KMT2ACCR2 | |
| SCHEMBL15966984 | 0.85 | NAMPT (0.47) | CCR2KCNH2 | |
| SCHEMBL29658402 | 0.84 | POLB (0.59) | ALDH1A1POLBMEN1KMT2ACCR2 | |
| SCHEMBL3776688 | 0.80 | CCR2 (0.49) | ALDH1A1POLBCCR2KCNH2 | |
| SCHEMBL5513102 | 0.80 | POLB (0.56) | ALDH1A1POLBCCR2TP53BP1 | |
| Hydrochloric Acid SCHEMBL709535 | 0.79 | POLB (0.55) | ALDH1A1POLBCCR2TP53BP1 | |
| SCHEMBL5513140 | 0.79 | HDAC6 (0.51) | ALDH1A1POLBMEN1KMT2ACCR2 | |
| SCHEMBL3778064 | 0.78 | CACNA1H (0.43) | ALDH1A1POLBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | ALDH1A1 2267/4885POLB 3782/4885MEN1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.